Cancer immunotherapy has revolutionized cancer care, yet most patients still fail to respond. A new study reveals how cancer cells package the immune-suppressing protein PD-L1 into tiny extracellular vesicles, undermining immunotherapy’s effectiveness. Remarkably, the researchers identify a common class of cholesterol-lowering drugs—statins—as powerful inhibitors of this process. By uncovering a hidden mechanism of immune resistance and a readily available way to block it, the study opens new avenues for improving cancer immunotherapy outcomes.

A newly approved National Cancer Institute-funded clinical trial aims to improve survival for head and neck cancer patients whose disease returns after radiation therapy – a setback that affects up to 40% of patients and is often associated with poor outcomes.